2026-04-13T02:45:42Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4789832024-12-20T06:13:54Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Girschikofsky, Michael author Arico, Maurizio author Castillo, Diego author Chu, Anthony author Doberauer, Claus author Fichter, Joachim author Haroche, Julien author Kaltsas, Gregory A. author Makras, Polyzois author Marzano, Angelo V. author De Menthon, Mathilde author Micke, Oliver author Passoni, Emanuela author Seegenschmiedt, Heinrich M. author Tazi, Abdellatif author McClain, K.L. author Universitat Autònoma de Barcelona author 2013 Langerhans Cell Histiocytosis (LCH) is an orphan disease of clonal dendritic cells which may affect any organ of the body. Most of the knowledge about the diagnosis and therapy is based on pedriatic studies. Adult LCH patients are often evaluated by physicians who focus on only the most obviously affected organ without sufficient evaluation of other systems, resulting in patients being underdiagnosed and/or incompletely staged. Furthermore they may be treated with pediatric-based therapies which are less effective and sometimes more toxic for adults. The published literature on adult LCH cases lacks a comprehensive discussion on the differences between pediatric and adult patients and there are no recommendations for evaluation and comparative therapies. In order to fill this void, a number of experts in this field cooperated to develop the first recommendations for management of adult patients with LCH. Key questions were selected according to the clinical relevance focusing on diagnostic work up, therapy, and follow up. Based on the available literature up to December 2012, recommendations were established, drafts were commented by the entire group, and redrafted by the executive editor. The quality of evidence of the recommendations is predominantly attributed to the level of expert opinion. Final agreement was by consensus. © 2013 Girschikofsky et al.; licensee BioMed Central Ltd. Adult Histiocytosis Langerhans Management of adult patients with Langerhans cell histiocytosis : Recommendations from an expert panel on behalf of Euro-Histio-Net